{"id":"W2103845135","doi":"10.1200/jco.2012.30.15_suppl.8502","title":"Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with <i>BRAF<sup>V600E</sup></i>-mutated melanoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":140,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Vemurafenib; Dacarbazine; Hazard ratio; Internal medicine; Interim analysis; Temozolomide; Metastatic melanoma; Gastroenterology; Oncology; Surgery; Randomized controlled trial; Confidence interval; Chemotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005730469,0.0004801548,0.003068575,0.0001464015,0.00009661718,0.00006822674,0.0006197964,0.0006534298,0.00002049836],"category_scores_gemma":[0.002600763,0.0003150739,0.000320329,0.0001911736,0.0003084009,0.00008963889,0.0002601761,0.0007347792,0.000005678904],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001022697,"about_ca_system_score_gemma":0.0008952728,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009847146,"about_ca_topic_score_gemma":0.0002814286,"domain_scores_codex":[0.9926344,0.00169725,0.003840567,0.0005898764,0.0004241267,0.0008138216],"domain_scores_gemma":[0.9939601,0.001265809,0.002920646,0.0004388299,0.0007790429,0.0006355163],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9672881,0.0108556,0.01359735,0.00002731755,0.001113146,0.00009604257,0.0001969924,0.0001607165,0.001141771,0.00002721094,0.003096011,0.002399708],"study_design_scores_gemma":[0.9407884,0.03477335,0.001660775,0.0001530991,0.0006439649,0.00004974231,0.00005275258,0.0009996195,0.00120943,0.0000103959,0.01923192,0.0004264856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936966,0.0002200617,0.0004225175,0.0003208299,0.0009605181,0.003437313,0.00008958283,0.00001306331,0.0008395131],"genre_scores_gemma":[0.9940383,0.0001171389,0.002605995,0.0005763213,0.001456989,0.00008943947,0.0008610373,0.0000642579,0.0001904604],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02649966,"threshold_uncertainty_score":0.9999301,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07959961057608907,"score_gpt":0.3936601599823536,"score_spread":0.3140605494062645,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}